Yifan Pharmaceutical Co., Ltd. - Laporan Laba Rugi (TTM)

Yifan Pharmaceutical Co., Ltd.
CN ˙ SZSE ˙ CNE000001K65
CN¥ 15.58 ↑0.59 (3.94%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Yifan Pharmaceutical Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 5,533 5,400 5,276 4,967 4,656 4,409 4,115 3,801 3,740 3,837 3,869 4,011 4,038 4,068 4,456 4,756 4,996 5,160 5,160 5,163
Change (%) -2.40 -2.30 -5.85 -6.27 -5.30 -6.68 -7.62 -1.59 2.57 0.85 3.67 0.67 0.74 9.52 6.75 5.04 3.28 0.01 0.05
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 2,799 2,899 3,034 3,004 2,820 2,594 2,300 2,035 1,905 1,983 2,037 2,093 2,100 2,159 2,376 2,566 2,731 2,808 2,821 2,785
Change (%) 3.58 4.63 -0.98 -6.12 -8.00 -11.34 -11.52 -6.40 4.13 2.69 2.76 0.32 2.83 10.06 7.99 6.44 2.79 0.48 -1.26
% of Revenue 50.59 53.69 57.50 60.47 60.57 58.84 55.90 53.54 50.92 51.70 52.64 52.18 52.00 53.07 53.33 53.95 54.67 54.41 54.66 53.95
Gross Operating Profit 2,734 2,501 2,243 1,963 1,836 1,815 1,815 1,766 1,836 1,853 1,833 1,918 1,938 1,909 2,079 2,190 2,265 2,352 2,340 2,377
Change (%) -8.52 -10.33 -12.44 -6.50 -1.14 -0.02 -2.68 3.95 0.95 -1.12 4.68 1.05 -1.51 8.92 5.33 3.40 3.86 -0.54 1.62
% of Revenue 49.41 46.31 42.50 39.53 39.43 41.16 44.10 46.46 49.08 48.30 47.36 47.82 48.00 46.93 46.67 46.05 45.33 45.59 45.34 46.05
SG&A 1,097 1,120 1,143 1,207 1,269 1,318 1,345 1,378 1,482 1,465 1,476 1,516 1,480 1,563 1,648 1,709 1,754 1,691 1,689 1,649
Change (%) 2.08 2.11 5.56 5.11 3.92 2.02 2.42 7.61 -1.20 0.79 2.68 -2.39 5.66 5.41 3.74 2.59 -3.60 -0.10 -2.38
% of Revenue 19.82 20.73 21.67 24.30 27.25 29.90 32.69 36.24 39.63 38.17 38.15 37.79 36.64 38.43 36.98 35.94 35.10 32.77 32.73 31.94
R&D 233 325 307 318 309 197 194 190 194 190 199 212 235 312 325 317 319 292 296 296
Change (%) 39.91 -5.71 3.66 -2.85 -36.35 -1.12 -2.35 2.37 -2.14 4.84 6.55 10.69 32.83 3.96 -2.25 0.54 -8.52 1.24 0.14
% of Revenue 4.20 6.02 5.81 6.40 6.64 4.46 4.73 5.00 5.20 4.96 5.15 5.30 5.82 7.68 7.29 6.67 6.39 5.66 5.73 5.73
OpEx 4,213 4,386 4,518 4,570 4,431 4,146 3,844 3,599 3,571 3,665 3,784 3,912 3,902 4,067 4,340 4,550 4,786 4,834 4,898 4,849
Change (%) 4.12 2.99 1.15 -3.03 -6.43 -7.30 -6.38 -0.78 2.65 3.23 3.39 -0.24 4.22 6.71 4.83 5.19 1.00 1.33 -1.00
% of Revenue 76.14 81.23 85.63 92.00 95.18 94.04 93.42 94.68 95.46 95.53 97.79 97.52 96.64 99.97 97.41 95.66 95.80 93.68 94.91 93.92
Operating Income 1,320 1,014 758 398 224 263 271 202 170 171 86 99 136 1 116 206 210 326 263 314
Change (%) -23.19 -25.21 -47.57 -43.55 17.05 3.11 -25.31 -16.07 0.93 -50.05 16.20 36.41 -99.20 10,517.34 78.56 1.73 55.31 -19.46 19.60
% of Revenue 23.86 18.77 14.37 8.00 4.82 5.96 6.58 5.32 4.54 4.47 2.21 2.48 3.36 0.03 2.59 4.34 4.20 6.32 5.09 6.08
Interest Expense -77 -71 -65 -61 -63 -75 -80 -88 -93 -86 -85 -82 -76 -76 -72 -68 -70 -69 -66 -61
Change (%) -7.63 -8.38 -6.32 2.82 18.93 6.93 9.90 6.18 -7.75 -0.63 -4.22 -6.86 -0.71 -5.15 -4.86 2.91 -1.51 -4.76 -6.58
% of Revenue -1.39 -1.32 -1.23 -1.23 -1.35 -1.69 -1.94 -2.31 -2.49 -2.24 -2.20 -2.04 -1.88 -1.86 -1.61 -1.43 -1.40 -1.34 -1.28 -1.19
Net Income 1,073 968 777 463 348 278 267 226 191 191 135 139 135 -551 -470 -407 -332 386 393 436
Change (%) -9.71 -19.74 -40.41 -24.89 -19.97 -3.94 -15.56 -15.47 0.17 -29.54 3.41 -3.24 -508.78 -14.76 -13.46 -18.44 -216.42 1.83 11.03
% of Revenue 19.39 17.93 14.73 9.32 7.47 6.31 6.50 5.94 5.10 4.98 3.48 3.47 3.34 -13.55 -10.54 -8.55 -6.64 7.48 7.62 8.45

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista